Cargando…

Safety of ACE-I and ARB medications in COVID-19: A retrospective cohort study of inpatients and outpatients in California

INTRODUCTION: There is significant interest in the use of angiotensin converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers (ARB) in coronavirus disease 2019 (COVID-19) and concern over potential adverse effects since these medications upregulate the severe acute respiratory synd...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rubin, Samuel J. S., Falkson, Samuel R., Degner, Nicholas R., Blish, Catherine A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605244/ https://www.ncbi.nlm.nih.gov/pubmed/34611496 http://dx.doi.org/10.1017/cts.2020.489

Ejemplares similares

Clinical characteristics associated with COVID-19 severity in California
por: Rubin, Samuel J. S., et al.
Publicado: (2020)

ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs
por: Lee, Ivan T., et al.
Publicado: (2020)

Controversy regarding ACE inhibitors / ARBs in COVID-19
por: Soria Arcos, Federico, et al.
Publicado: (2020)

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)

ACE-I/ARB Therapy prior to Contrast Exposure: What Should the Clinician Do?
por: Kalyesubula, Robert, et al.
Publicado: (2014)

What Evidence Supports Guidelines for Use of ACE Inhibitors and ARBs in Diabetes?
por: Curtiss, Frederic R.
Publicado: (2006)

ASSOCIATION BETWEEN IN-HOSPITAL MORTALITY AND ACE/ARB INHIBITOR USAGE
por: Ruge, Max, et al.
Publicado: (2022)

COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients
por: Sieńko, Jerzy, et al.
Publicado: (2020)

COVID-19-related deaths not increased with ACE inhibitor or ARB use
Publicado: (2020)

The effect of ACE inhibitors and ARBs on outcomes in hospitalized patients with COVID-19
por: Najafi, Narges, et al.
Publicado: (2022)

Safety of ACEi and ARB in COVID‐19 management: A retrospective analysis
por: Kumar, Sabina, et al.
Publicado: (2022)

Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients
por: Rossi, Gian Paolo, et al.
Publicado: (2020)

The concern about ACE/ARB and COVID-19: Time to hold your horses!
por: Pergolizzi, Joseph V., et al.
Publicado: (2020)

ACE Inhibitor and ARB Utilization and Expenditures in the Medicaid Fee-For-Service Program from 1991 to 2008
por: Bian, Boyang, et al.
Publicado: (2010)

149 Association of ACE-I and ARB Prescriptions With Mortality in Patients Admitted to the Hospital With COVID-19 in New York City
por: Barrett, B., et al.
Publicado: (2020)

The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19
por: Braude, Philip, et al.
Publicado: (2020)

SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs
por: Ciulla, Michele M.
Publicado: (2020)

Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs
por: Byttebier, Geert, et al.
Publicado: (2021)

In silico prediction of ARB resistance: A first step in creating personalized ARB therapy
por: Anderson, Shane D., et al.
Publicado: (2020)

Clinical Impact of ACE-I/ARB for Conservatively Treated Patients with Moderate to Severe Mitral Regurgitation: A Single Center Observational Study
por: Uzel, Robert, et al.
Publicado: (2023)

Antihypertensive medication uses and serum ACE2 levels: ACEIs/ARBs treatment does not raise serum levels of ACE2
por: Emilsson, Valur, et al.
Publicado: (2020)

Continue ACE inhibitors / ARB’S till further evidence in coronavirus disease 2019 (COVID-19)
por: Bansal, Sandeep, et al.
Publicado: (2020)

Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis
por: Flacco, Maria Elena, et al.
Publicado: (2020)

NO EXCESS MORTALITY ASSOCIATED WITH CONCOMITANT ACE INHIBITOR OR ARB USE IN HOSPITALIZED PATIENTS WITH COVID-19
por: Annie, Frank H., et al.
Publicado: (2021)

SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy
por: Chung, Mina K., et al.
Publicado: (2020)

ACE-I AND ARBS DO NOT INFLUENCE THE CHEST CT PRESENTATION AND 1-YEAR SURVIVAL OF COVID-19 PATIENTS: ITALIAN MULTICENTER REGISTRY
por: Birtolo, Lucia Ilaria, et al.
Publicado: (2022)

Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ
por: Duprez, Daniel, et al.
Publicado: (2011)

A historical perspective on ACE2 in the COVID-19 era
por: Bhalla, Vivek, et al.
Publicado: (2020)

Physician Conformity and Patient Adherence to ACE Inhibitors and ARBs in Patients With Diabetes, With and Without Renal Disease and Hypertension, in a Medicaid Managed Care Organization
por: Cooke, Catherine E., et al.
Publicado: (2006)

Cardiovascular risk reduction by reversing endothelial dysfunction:ARBs, ACE inhibitors, or both? Expectations from The ONTARGET Trial Programme
por: Ruilope, Luis Miguel, et al.
Publicado: (2007)

Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?
por: Novo, Salvatore, et al.
Publicado: (2009)

Impact of Beta-blocker, ACE Inhibitor, and ARB therapy on thoracic aorta wall shear stress in bicuspid aortic valve patients
por: McGee, Katherine, et al.
Publicado: (2016)

ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking
por: Onweni, Chidinma L., et al.
Publicado: (2020)

Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE
por: Dobrowolski, Chrisanna, et al.
Publicado: (2023)

From ARB to ARNI in Cardiovascular Control
por: Uijl, Estrellita, et al.
Publicado: (2016)

Repurposing ARBs as treatments for breast cancer
por: George, Amee J., et al.
Publicado: (2017)

The histological spectrum of ARB‐induced gastritis
por: Storozuk, Tanner, et al.
Publicado: (2022)

Need to Revisit Step Therapy for ARBs
por: Ram, C. Venkata, et al.
Publicado: (2007)

From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy
por: Matsoukas, John, et al.
Publicado: (2021)

Efficacy of ARB/HCTZ Combination Therapy in Uncontrolled Hypertensive Patients Compared with ARB Monotherapy: A Meta-Analysis
por: Ma, Linlin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dfs3sp1smacj1q7n32a6dis8gn